An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 Aug 2013 New trial record